This article is more than 5 years old. Information may no longer be current.
Multimatrix mesalazine improved work-related outcomes in adults with UC
Click Here to Manage Email Alerts
Patients with mild-to-moderate active ulcerative colitis symptoms who received multimatrix mesalazine showed improvements in work-related outcomes within 3 and 8 weeks of treatment, but outcomes were varied up to 12 months, according to study data
Adults with active mild-to-moderate UC (n=722; n=639 completed acute phase) were enrolled in an open-label, multi-country trial. During the 8-week acute phase, patients received 4.8 g/day of multimatrix mesalazine once daily. Those who achieved partial or complete remission at 8 weeks were given 2.4 g/day daily.
Work-related outcomes were assessed at baseline, week 3, week 8 and at 12 months for those who remained in the trial. Absenteeism, presenteeism, overall work impairment and activity impairment were assessed for employed participants. Those who were not employed were assessed on activity impairment only.
Post-hoc comparisons after 3 weeks showed improvements in all domains, and improvements were seen in activity impairment, overall work impairment and presenteeism from 3 to 8 weeks.
Among the 469 patients who entered the maintenance phase after 8 weeks and up to 12 months, improvements in presenteeism and activity impairment lessened, although absenteeism and overall work impairment were unchanged.
Disclosure: Relevant financial disclosures were not provided.
Click Here to Manage Email Alerts